Merck KGaA (Darmstadt, Germany), a privately-held pharmaceutical and specialist chemicals company, has acquired the assets of chromatographic column developer SeQuant AB (Umea, Sweden). "[The aquisition] offers Merck superb opportunities for the future expansion of the chromatography business," said Klaus Bischoff, head of the Performance and Life Science Chemicals division at Merck.
Merck KGaA (Darmstadt, Germany), a privately-held pharmaceutical and specialist chemicals company, has acquired the assets of chromatographic column developer SeQuant AB (Umea, Sweden). "[The aquisition] offers Merck superb opportunities for the future expansion of the chromatography business," said Klaus Bischoff, head of the Performance and Life Science Chemicals division at Merck. SeQuant is particulary known for its particle technology development for zwitterionic hydrophilic interaction chromatography, or ZIC(R)-HILIC, a proprietary concept that "markedly improves the separation of... chemical compounds," such as inorganic ions and polar organic ions, including peptides, according to the company.
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.